Last reviewed · How we verify
SARS-Cov-2 Vaccine Inactivated
This vaccine works by introducing inactivated SARS-Cov-2 virus to stimulate an immune response.
This vaccine works by introducing inactivated SARS-Cov-2 virus to stimulate an immune response. Used for Prevention of SARS-Cov-2 infection.
At a glance
| Generic name | SARS-Cov-2 Vaccine Inactivated |
|---|---|
| Also known as | Inactivated vaccine |
| Sponsor | Livzon Pharmaceutical Group Inc. |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The inactivated virus is used to trigger the production of antibodies and immune cells that can recognize and fight the SARS-Cov-2 virus. This immune response helps to protect against future infections.
Approved indications
- Prevention of SARS-Cov-2 infection
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (PHASE2)
- Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study (PHASE4)
- Vaccine Responses in Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-Cov-2 Vaccine Inactivated CI brief — competitive landscape report
- SARS-Cov-2 Vaccine Inactivated updates RSS · CI watch RSS
- Livzon Pharmaceutical Group Inc. portfolio CI